Business Context and Reporting Period
This Form 8-K Current Report was filed by Gossamer Bio, Inc. on September 21, 2021, covering events occurring on September 16, 2021. The filing primarily addresses executive leadership changes and associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and equity grants.
Material Changes
- Executive Promotion: Bryan Giraudo was promoted to Chief Operating Officer and Chief Financial Officer, effective September 16, 2021.
- Compensation Adjustment: Mr. Giraudo's annual base salary was increased to $460,000, and his target annual incentive bonus was set at 45% of his base salary.
- Equity Grant: The Company granted Mr. Giraudo an option to purchase 150,000 shares of common stock under the 2019 Equity Incentive Plan. The exercise price equals the closing price on September 16, 2021.
- Vesting Schedule: 25% of the option vests on September 16, 2022, with the remainder vesting in 36 equal monthly installments thereafter.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business operations. It details severance benefits under Mr. Giraudo's existing employment agreement, including 9 months of base salary (increasing to 12 months in a change of control scenario) and continued health coverage, payable upon termination without cause or resignation for good reason.
Investor Verification Checklist
- Verify the closing stock price on September 16, 2021, to determine the exercise price of the 150,000 share option grant.
- Review the Company's 2021 Proxy Statement (Schedule 14A) for Bryan Giraudo's full biography.
- Confirm the terms of the Existing Employment Agreement referenced in the 2020 Form 10-K (Exhibit 10.10) regarding severance triggers.
- Monitor future filings for the impact of the new CFO/COO leadership on financial reporting and operational strategy.